Historic Manchester mill converted into advanced biotechnology engineering facility
A historic mill in Manchester’s Amoskeag Millyard has been converted into an advanced biotechnology engineering facility, according to a June 24 report from EwingCole. The facility’s stated purpose includes manufacturing human organs.
The conversion repurposes a building that was formerly used to process animal hides. It places a specialized biotechnology-focused use inside one of Manchester’s best-known historic industrial areas, rather than presenting the project as a new construction development.
What the project is intended to do
The available documentation describes the renovated site as a biotechnology engineering facility focused on manufacturing human organs. That is the project’s stated purpose; the report does not say that transplantable organs are already being produced there or used in clinical care.
The project is significant as an adaptive-reuse development: a former industrial mill has been refitted for a highly specialized engineering and biological-manufacturing purpose. The report identifies the location as the Amoskeag Millyard in Manchester, New Hampshire.
For Manchester, the conversion illustrates how historic industrial space can be adapted for life-sciences and commercialization-related infrastructure. The documented development is the physical transformation of the mill into a biotechnology facility, not a reported research result, clinical outcome or commercial product launch.
What remains unknown
Available source material does not identify the facility’s operating company. It also does not provide an investment amount, staffing figures, production capacity, construction timeline beyond the June 24, 2026 report, or details about the facility’s regulatory status.
Those omissions limit what can be concluded about the project’s current stage. The source supports that the facility has been transformed and that its stated focus includes human-organ manufacturing, but it does not document approval for clinical use, actual organ production, or the number of people who may work at the site.
A shift in use for the millyard
The development links the site’s former role in animal-hide processing with a new biotechnology engineering purpose. EwingCole presented the project as a major adaptive-reuse and life-sciences development in its June 24, 2026 report.
No next construction milestone, opening date, regulatory deadline or production target was provided in the available documentation. Further information from the project’s operator or regulators would be needed to determine when, or whether, the facility moves from its described engineering purpose to any clinical or commercial application.